British Pound: Political risks and BoE stance – RaboResearch
RaboResearch Global Economics & Markets discusses recent UK CPI and labour data and their implications for the Pound, and GBP/USD. The bank notes softer UK inflation, signs of spare capacity in the labour market and tighter financial conditions. It highlights BoE caution, elevated market rates and UK political risks, expecting EUR/GBP near 0.87 and GBP/USD dips towards 1.33 over 1–3 months.
BoE caution and UK political uncertainty
"The pound has already recouped most of the losses made vs. the EUR on this morning’s release of softer than expected May UK CPI inflation data. The headline rate at 2.8% y/y, held steady in line with the previous month’s figure while the core rate ticked only slightly higher to 2.6% y/y. The data indicates that this year’s peak in UK inflation could be lower than has been expected."
"We continue to expect EUR/GBP to creep higher to the 0.87 area on a 1-to-3-month view."
"Despite the weakness in the UK labour data, the market was quick to price in a fairly aggressive spate of tightening from the BoE at the start of the Iran war. Some of this has now been reversed, but the movement in market rates has tightened monetary conditions. This in itself may allow the MPC to sit on its hands for longer, or at least to allow policymakers to wait for more news regarding the direction of oil prices."
"The focus will instead be on both the minutes and the voting pattern of policymakers as the market looks for clues as to whether the MPC could even sidestep a rate hike altogether this year. That said, even policy doves may conclude that in order to avoid an official rate hike, market rates may need to stay elevated for now. This raises the risk that the Bank continues to talk tough over the summer."
"This risk alone, is likely to unsettle the pound. We see risk of dips in cable back towards the 1.33 area on a 1-to-3 month view."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Microsoft (MSFT.US) Ignite Conference Releases Six Dedicated AI Models: Challenging OpenAI and Anthropic with Lower Costs
Microsoft is making significant progress in building its own cutting-edge general-purpose AI models and has launched six dedicated AI models at the Ignite conference.

A key return for the $10.6 billion acquisition! GlaxoSmithKline (GSK.US) lung cancer drug Nelkarmi approved for market launch, targeting a multi-billion dollar market
The lung cancer drug neladalkib from GlaxoSmithKline has been approved for market by the US Food and Drug Administration (FDA), further validating the strategic value of the British pharmaceutical company's previous acquisition of the biotechnology company Nuvalent.
Hyperliquid revenue diversification rises as $4B daily volume shifts from crypto to stocks

ARK Invest buys $40 million in crypto stocks, sells $84.8 million in Nvidia shares
